EUVIMEDEUVIMED entdecken
Crossref

In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter

Meylis Artykov, Esin Ozcelebi, Mehmet Yildirim Sara, Ahmet Gudeloglu, Alper Bektas Iskit, Fazil Tuncay Aki

Neurourology and Urodynamics · 2024

DOI: 10.1002/nau.25483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurourology and Urodynamics, 2024. Verfasst von Meylis Artykov und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hacettepe University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Acetanilides, Thiazoles, Ureter, Adrenergic beta-3 Receptor Agonists. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Hacettepe Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to investigate the effect of mirabegron, a β3‐adrenoceptor agonist with widespread clinical use for treating overactive bladder disease, on isolated healthy human ureter strips. Materials and Methods This was a prospective study employing a series of in vitro organ bath experiments using ureteral tissues of kidney grafts from 10 healthy donors. The ureteral strips were subjected to cumulative mirabegron concentrations (10 −9 –10 −4.5 M). Effects on frequency or amplitude of spontaneous, 10 mM KCl‐ or EFS‐induced contractions were evaluated.

Results

Mirabegron decreased the frequency of spontaneous ureteric contraction in a concentration‐dependent manner. Statistically significant decrease in the frequency of spontaneous contraction was observed at 10 −8 –10 −4.5 M. In 10 mM KCl medium, statistically significant change in frequency was observed at 10 −9 –10 −4.5 M. Statistically significant decrease in the amplitudes of spontaneous contraction was observed at 10 −7 –10 −4.5 M. In a 10 mM KCl medium, statistically significant change in amplitudes was observed at 10 −8 –10 −4.5 M.

Conclusions

Mirabegron reduced the amplitude and frequency of human ureter activity in in vitro organ bath studies. This effect was achieved in a dose‐dependent manner on isolated tissue strips. Although monotherapy with mirabegron remains uncertain, this study has the potential to elucidate the mechanism underlying the effectiveness of mirabegron, particularly in combination therapy for ureteral stones.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetanilidesThiazolesUreterAdrenergic beta-3 Receptor AgonistsMuscle ContractionHumansMaleFemaleProspective StudiesAdultMiddle AgedIn Vitro TechniquesDose-Response Relationship, Drug

Stichwörter der Autor:innen

human ureterin vitro studymirabegronureteric activityβ3‐adrenoceptor agonist

Substanzen

mirabegronAcetanilidesThiazolesAdrenergic beta-3 Receptor Agonists

Autor:innen und Institutionen

  • Department of Urology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Department of Pharmacology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Förderung

  • Hacettepe Üniversitesi

Zitieren

APA

Artykov, M., Ozcelebi, E., Sara, M. Y., Gudeloglu, A., Iskit, A. B., & Aki, F. T. (2024). In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25483

Vancouver

Artykov M, Ozcelebi E, Sara MY, Gudeloglu A, Iskit AB, Aki FT. In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter. Neurourology and Urodynamics. 2024. doi:10.1002/nau.25483

BibTeX
@article{Artykov2024,
  author = {Artykov, Meylis and Ozcelebi, Esin and Sara, Mehmet Yildirim and Gudeloglu, Ahmet and Iskit, Alper Bektas and Aki, Fazil Tuncay},
  title = {In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter},
  journal = {Neurourology and Urodynamics},
  year = {2024},
  doi = {10.1002/nau.25483}
}
Kostenlos starten →